Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Orchard Therapeutics

Orchard Therapeutics

Orchard Therapeutics is a biotechnology company developing gene therapies for rare diseases.

Orchard Therapeutics is a biotechnology company developing gene therapies for patients with rare diseases. The company has a portfolio of approved ex vivo gene therapies.


September 9, 2021
Orchard Therapeutics appoints Nicoletta Loggia as chief technical officer and Fulvio Mavilio as Chief Scientific Officer, Leslie Meltzer promoted to chief medical officer.
February 5, 2021
Orchard Therapeutics raises a $150,000,000 venture round from Avidity Partners, Casdin Capital, Farallon Capital Management, RA Capital Management and Surveyor Capital.
August 2018
Orchard Therapeutics raises a $150,000,000 series C round from Deerfield Capital Management, Driehaus Capital Management, Foresite Capital, Medison Ventures, Perceptive Advisors, RTW Investments LLC, Temasek Holdings and Venrock.
December 20, 2017
Orchard Therapeutics raises a $110,000,000 series B round from Agent Capital, Baillie Gifford, Pavilion Capital, RTW Investments LLC, Temasek Holdings and UCL Technology Fund.
November 23, 2016
Orchard Therapeutics raises a $20,000,000 grant from California Institute for Regenerative Medicine.
May 3, 2016
Orchard Therapeutics raises a $29,660,000 series A round from AlbionVC and UCL Technology Fund.
Orchard Therapeutics was founded by Andrea Spezzi, Ben Auspitz and Bobby Gaspar.

Funding Rounds


Further Resources


Orchard Therapeutics Announces the Build-out of New Gene Therapy Manufacturing Facility in California

Orchard Therapeutics



Kyle LaHucik
September 9, 2021
Gene therapy biotech Orchard Therapeutics has picked a shiny apple from Novartis, bringing Nicoletta Loggia, Ph.D. on as chief technical officer after a 17-year career at the Swiss pharma. Loggia previously served as global head of cell and gene therapies for Novartis--a high profile part of the pharma's business that in recent years has launched Zolgensma.
Annalee Armstrong
May 11, 2021
Three years after receiving a gene therapy from Orchard Therapeutics in an early-stage clinical trial, 100% of patients with an inherited disease that damages the immune system were still alive, according to a new study published in the New England Journal of Medicine today.
AGC Biologics
January 4, 2021
/PRNewswire/ -- AGC Biologics, destacada organización farmacéutica líder en desarrollo de contratos y fabricación (CDMO), es el primer fabricante del producto...
November 19, 2020
Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for OTL-200, an autologous, hematopoietic stem cell, lentiviral vector-based gene therapy in development for the treatment of metachromatic leukodystrophy (MLD). The company also has applied for Regenerative Medicine Advanced Therapy (RMAT) des
Krystle Vermes
June 9, 2020
Lundbeck stated that it is optimizing its research and development organization to strengthen and advance its pipeline.


Golden logo
By using this site, you agree to our Terms & Conditions.